Cerebrolysin: A Brain-Derived Peptide Preparation with Neurotrophic Properties and Clinical Evidence in Alzheimer's Disease | Research

The takeaway

Cerebrolysin, a peptide mixture derived from brain proteins, showed nerve growth factor-like activity in lab studies and improved cognitive function in Alzheimer's patients with effects lasting up to 6 months after treatment stopped.

Benefits persisted 6 months post-treatment
Alzheimer's patients showed detectable cognitive improvement half a year after stopping Cerebrolysin, suggesting the drug triggers brain repair rather than just symptom relief

What the researchers found

Cerebrolysin demonstrated dual neurotrophic and neuroprotective activity across multiple experimental models, promoting nerve cell growth in both peripheral and central nervous system neurons and protecting against various types of neuronal damage.

In clinical trials with Alzheimer's disease patients, Cerebrolysin produced rapid improvement in overall patient state, particularly cognitive performance. Most notably, these improvements were long-lasting — detectable even 6 months after stopping treatment. This persistence suggests the drug may induce actual repair processes rather than simply providing temporary symptomatic relief. The drug showed extremely high tolerability with no reports of serious side effects, a significant advantage over natural neurotrophic factors which cause problems like hyperalgesia and weight loss.

Why it matters

Natural neurotrophic factors have long been considered promising treatments for neurodegenerative diseases, but they've been stymied by the blood-brain barrier and side effects. Cerebrolysin represents an alternative strategy — using smaller peptide fragments that can potentially overcome these delivery challenges while retaining the beneficial biological activity. The finding that cognitive improvements persist months after treatment cessation is particularly significant, as it suggests disease-modifying rather than merely symptomatic effects.

How the study worked

This is a review paper summarizing preclinical and clinical research on Cerebrolysin. The preclinical work included in vitro and in vivo studies examining neurotrophic effects on different neuronal populations and neuroprotective properties after various types of lesions, with behavioral testing of learning and memory. Clinical evidence comes from trials in Alzheimer's disease patients assessing cognitive performance and overall clinical state, with follow-up periods extending to 6 months post-treatment.

What this study cannot tell us

This is a narrative review, not a systematic review or meta-analysis, so there is potential for selective reporting. The clinical trial data described lacks specific patient numbers, effect sizes, or statistical analyses in the abstract. The review is authored by researchers associated with Cerebrolysin research, raising potential conflict of interest. The paper is from 1998, and the clinical evidence described was preliminary. Cerebrolysin's exact mechanism of action and which specific peptides are responsible for its effects remain unclear.

How to read the evidence

This is a narrative review summarizing preclinical and early clinical data. While it describes clinical trials in Alzheimer's patients, specific trial details (sample sizes, controls, effect sizes) are not provided. The evidence is suggestive but not definitive.

When this study was published

Published in 1998, this is a nearly 30-year-old review. Cerebrolysin has since been studied in larger trials with mixed results. It is approved in some countries but not by the FDA. More recent systematic reviews should be consulted for current evidence assessment.

The bigger picture

This 1998 review captures an early but important chapter in the story of peptide-based neurotherapeutics. While large neurotrophic factors like NGF and BDNF struggled with delivery and safety, Cerebrolysin showed that smaller peptide fragments could retain neurotrophic activity with better tolerability. The concept of using enzymatically processed brain-derived peptides as a drug has continued to be studied, and Cerebrolysin remains in clinical use in some countries for stroke and traumatic brain injury, though it has not gained FDA approval in the United States.

Questions still open

Which specific peptides within Cerebrolysin are responsible for its neurotrophic and neuroprotective effects?
Have large-scale, placebo-controlled trials since 1998 confirmed the cognitive benefits and long-lasting effects in Alzheimer's patients?
Could the peptide engineering approach used in Cerebrolysin be refined to create more targeted neurotrophic peptide therapies?

Common questions

What is Cerebrolysin and how is it made?

Cerebrolysin is a drug made by breaking down purified pig brain proteins into small peptide fragments using standardized enzymes. The resulting mixture contains biologically active peptides that mimic the effects of natural brain growth factors like nerve growth factor (NGF). Because these peptides are smaller than the original proteins, they may be better able to reach the brain and have fewer side effects.

Why isn't Cerebrolysin available in the United States?

Cerebrolysin has not received FDA approval in the United States, partly because the evidence from clinical trials has been mixed and the drug's exact composition is complex and difficult to fully characterize. While some studies show cognitive benefits, larger and more rigorous trials have not consistently replicated the early positive findings. It remains available by prescription in many other countries.

Read the original research

Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.

Journal of neural transmission. Supplementum, 53, 289-98

View on PubMed ↗

Citation

Windisch, M; Gschanes, A; Hutter-Paier, B. (1998). Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.. Journal of neural transmission. Supplementum, 53, 289-98.